In patients with monoclonal gammopathy of undetermined significance (MGUS) the increase of bone turnover rate can increase the risk of fracture. Thus, a treatment normalizing this negative balance could be of benefit in these patients. We studied 100 patients affected by MGUS, grouped according to the presence (group A, 50 patients) or absence (group B) of vertebral fractures and/or osteoporosis. Group A was treated with alendronate (70 mg/weekly) plus calcium and cholecalciferol for 18 months, and group B was treated with calcium and cholecalciferol. After 18 months, the mean bone mineral density (BMD) of the lumbar spine and total femur had increased by 6.1% and 1.5%, respectively, in group A. In the nine patients of this group not taking alendronate, BMD values of the lumbar spine and total femur decreased by 1.6% (P <= 0.001) and 1.3% (P <= 0.01), respectively. In patients of group B, BMD increased by 1.2% at the lumbar spine and decreased by 1.2% at the total femur. Corresponding figures of those patients in the same group not taking calcium and vitamin D supplementation were -0.1% and -1.2%, respectively. At 18 months we observed significant decreases of serum bone markers: the difference between the groups was -23.2 (P <= 0.01) for bone alkaline phosphatase, -23.6 for osteocalcin (P <= 0.01), -35.1 for C-terminal telopeptides of collagen type I (P <= 0.001), and -0.47 for bone sialoprotein (P = nonsignificant). Treatment with alendronate could lead to a significant reduction in fracture risk in MGUS patients with skeletal fragility.

The effects of alendronate treatment in osteoporotic patients affected by monoclonal Gammopathy of undetermined significance / Pepe, Jessica; Petrucci, Massimo; Mascia, MARIA LUCIA; Piemonte, Sara; Fassino, Valeria; Minisola, Salvatore. - In: CALCIFIED TISSUE INTERNATIONAL. - ISSN 0171-967X. - 82:6(2008), pp. 418-426. [10.1007/s00223-008-9145-2]

The effects of alendronate treatment in osteoporotic patients affected by monoclonal Gammopathy of undetermined significance

PEPE, JESSICA;PETRUCCI, Massimo;MASCIA, MARIA LUCIA;PIEMONTE, SARA;FASSINO, Valeria;MINISOLA, Salvatore
2008

Abstract

In patients with monoclonal gammopathy of undetermined significance (MGUS) the increase of bone turnover rate can increase the risk of fracture. Thus, a treatment normalizing this negative balance could be of benefit in these patients. We studied 100 patients affected by MGUS, grouped according to the presence (group A, 50 patients) or absence (group B) of vertebral fractures and/or osteoporosis. Group A was treated with alendronate (70 mg/weekly) plus calcium and cholecalciferol for 18 months, and group B was treated with calcium and cholecalciferol. After 18 months, the mean bone mineral density (BMD) of the lumbar spine and total femur had increased by 6.1% and 1.5%, respectively, in group A. In the nine patients of this group not taking alendronate, BMD values of the lumbar spine and total femur decreased by 1.6% (P <= 0.001) and 1.3% (P <= 0.01), respectively. In patients of group B, BMD increased by 1.2% at the lumbar spine and decreased by 1.2% at the total femur. Corresponding figures of those patients in the same group not taking calcium and vitamin D supplementation were -0.1% and -1.2%, respectively. At 18 months we observed significant decreases of serum bone markers: the difference between the groups was -23.2 (P <= 0.01) for bone alkaline phosphatase, -23.6 for osteocalcin (P <= 0.01), -35.1 for C-terminal telopeptides of collagen type I (P <= 0.001), and -0.47 for bone sialoprotein (P = nonsignificant). Treatment with alendronate could lead to a significant reduction in fracture risk in MGUS patients with skeletal fragility.
2008
alendronate; bone mineral density; bone turnover; monoclonal gammopathy of undetermined significance; monoclonal gammopathy of undetermined significance osteoporosis; osteoporosis
01 Pubblicazione su rivista::01a Articolo in rivista
The effects of alendronate treatment in osteoporotic patients affected by monoclonal Gammopathy of undetermined significance / Pepe, Jessica; Petrucci, Massimo; Mascia, MARIA LUCIA; Piemonte, Sara; Fassino, Valeria; Minisola, Salvatore. - In: CALCIFIED TISSUE INTERNATIONAL. - ISSN 0171-967X. - 82:6(2008), pp. 418-426. [10.1007/s00223-008-9145-2]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/106512
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 37
social impact